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a  b  s  t  r  a  c  t
Increasing access and frequency of human immunodeﬁciency virus testing are critical
to  stemming the epidemic. In Brazil’s concentrated epidemic, human immunodeﬁciency
virus  prevalence in the men who have sex with men/transgender population far exceeds
that  in the general population, but testing rates fall below what is needed to ensure early
detection  and treatment. Over-the-counter human immunodeﬁciency virus self-testing kits,
now available in stores in the U.S., have enormous potential to increase testing access
and  frequency and to facilitate early detection and treatment. With the advent of human
immunodeﬁciency  virus self-testing upon us, it is timely to engage the scientiﬁc community,
government,  and civil society in a dialog around how to best utilize this technology in Brazil.
We  summarize recent research on over-the-counter testing among men who have sex withome-based testing men, raise potential questions and challenges to using self-tests, suggest implementation
strategies,  and outline a research agenda moving forward.
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infection,8,9 and that increased testing alone could optimally
reduce  new infections by as much  as 1/3 in one year.10 Testing
remains  a high priority and must be made as widely acces-
sible  as possible, particularly to populations most at risk of
infection.
Brazil’s  HIV epidemic is concentrated among men  who
have  sex with men  (MSM)  and transsexual/transgender popu-
lations,  with elevated prevalence also occurring among sex
workers  and injection drug users.11 As compared to the gen-
eral  population, whose prevalence is stable at around 0.4–0.6%,
HIV  prevalence among MSM  in Brazil is estimated to be
between  13.6% and 14.4%.11–13 Nevertheless, studies have
demonstrated that only about half of Brazilian MSM report
any  history of testing,13–15 and that only 30% report testing
in  the past year.16 Currently the US Centers for Disease Con-
trol  and Prevention recommend that testing for most-at-risk
MSM  be conducted every 3–6 months.14 In a recently con-
ducted  national respondent driven sampling study, nearly
50%  of MSM  who  tested seropositive were  unaware of their
infection.13 Late diagnosis continues to be pervasive in Brazil,
particularly for men.17 Strategies to increase testing uptake
and  frequency among MSM  are needed.
On July 3 2012, the United States Food and Drug Administra-
tion  (US FDA) approved Over-the-Counter (OTC) licensing for
the saliva-based OraQuick In-Home HIV testTM (OraSure Tech-
nologies,  Inc., Bethlehem, PA).18 These tests are now available
in  US pharmacies, and a number of European nations are not
far  behind. In late 2013 the French Health Ministry announced
that  self-testing kits for HIV will be commercially available
in  2014;19 the United Kingdom recently lifted the ban on
HIV  home test kits, which should become available through
commercial channels by April 2014.20 The hope of OTC HIV
self-testing kits is that they will both facilitate testing for
communities at high risk of HIV transmission, particularly
those communities which are reticent to test, and increase
testing  frequency and thus early detection and treatment.
This  technology is particularly promising for MSM  and trans-
gender  populations, for whom negative experiences in the
public  health system, including long queues and discrimi-
nation  (related to sexual orientation, gender identity, or a
positive  HIV test), may  reduce their likelihood of clinic atten-
dance.
As  OTC HIV testing expands, the time to engage the sci-
entiﬁc  community, government, and civil society in a dialog
around  how to best utilize this technology in Brazil has come.
We  provide a brief review of recent research on utilization
and  acceptability of HIV self-testing for MSM, raise potential
implications of the OTC tests, and suggest potential strategies
for  implementation of self-testing and also a research agenda
moving  forward.
How  to  target  OTC  testing?
Since the idea of OTC HIV testing emerged in the nineties,
much  of the early debate centered on the issue of the quality
(sensitivity and speciﬁcity) of the kits and the risk proﬁle of
populations  targeted for test use. There is both the potential
for  false-negative results shortly after infection (the window
period)  and an increased burden of false-positive results if 1 4;1  8(3):239–244
self-testing is adopted by low prevalence populations, such
as  the “worried well” of repeat testers.21,22 However, self-
conducted HIV tests have generally performed quite well: a
recently published systematic review of both oral ﬂuid and
ﬁnger  stick self-conducted rapid HIV tests documented a
very  high speciﬁcity in supervised (with a health care worker
present)  and unsupervised (with a phone line for questions)
settings. The ﬁndings on sensitivity varied from 93% to 100%
in  unsupervised environments.23
Targeting home testing to particularly high-risk popula-
tions  can mitigate poor predictive values. If the OTC tests
currently  approved in the U.S. were  targeted to MSM  in Brazil,
both  the positive and negative predictive values of the test
would  be approximately 99% (assuming HIV prevalence of 10%
and OraSure sensitivity at 92% and speciﬁcity at 99.98% in the
home  environment).18 The extended ‘window period’ for anti-
body  detection of up to three months remains an unfortunate
reality. There is hope that the performance characteristics of
the  rapid tests will improve in coming years; however, the
antibody  tests will always have a window period and this lim-
itation  will always require careful orientation, particularly for
those with recent infections. Of course, the issue of the win-
dow  period exists for clinic-conducted rapid tests as well as
self-conducted tests; community education around the test-
ing  window remains a priority whether tests are conducted
alone  or in clinics. It also must be made clear to consumers
that self-tests cannot be used as a conﬁrmatory testing mech-
anism;  the test is not licensed for this purpose. To this end,
successful introduction of OTC testing will hinge on increas-
ing  awareness around the testing window and the limitations
of  the current rapid tests, particularly among health care
professionals and the non-governmental organizations (NGO)
community  who may  act as gate keepers.
Will  MSM  use  OTC  testing?
To date, published data indicate that MSM  are poised to use
self-tests.  Utilization data on self-testing among MSM  are
still  somewhat scarce, though a number of studies are cur-
rently  underway, including one in Rio de Janeiro, Brazil. One
landmark  study in New York provided home HIV tests to 27
non-condom using HIV-negative MSM with multiple partners
to  use for partner screening. Uptake of testing was  high: 101
partners  were self-tested over three months, and the major-
ity  of participants wanted to continue using home test kits
following  the study period.24 Other U.S.-based studies have
demonstrated that MSM  would use self-tests when given the
opportunity  and that they used them accurately.25,26 There
is  also ample data on speculative acceptability of self-testing
(not  based on actual experience). In Brazil, 90% of respondents
on  a national Internet survey with MSM reported that they
would  use HIV self-tests if provided the opportunity; over half
reported  a preference for self-testing as compared to clinic-
based  testing; and 60% of respondents said they would use
self-tests  to make choices about unprotected sex with sexual
partners.27 Similarly, acceptability studies conducted in the
US  among MSM demonstrate substantial interest in using HIV
home tests.25,28
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While the data on acceptability to date are encouraging,
here is still much  that is unknown about uptake of these
ests  outside of the research environment and about accept-
bility  within the diverse population that is often grouped
s  ‘MSM’. For example, there is little information regarding
cceptability among transgender populations. Little is known
bout  acceptability among health care providers who may  be
istributing test kits or attending populations presenting with
elf-testing  results. In fact, whether Brazilian MSM and other
t-risk  populations use the OTC tests when they become avail-
ble  may  depend to a large extent on the support of health
are  providers and encouragement from the NGO community;
 supportive environment can enable MSM  to access testing
ccording  to their needs. Self-testing may  offer an opportunity
o  bolster not only testing rates but also a sense of autonomy
r  empowerment in the MSM  community as they take control
f  their health.23
hat  about  counseling  and  linkage  to  care?
oluntary testing and counseling (VCT) has been a corner-
tone  of the Brazilian program since the ﬁrst HIV tests became
vailable  in the public system in 1985. In a country where qual-
ty  counseling has been emphasized, OTC tests raise a number
f  questions. How will counseling be offered in conjunction
ith  these tests? What counseling is needed before and after
he  test kit is acquired and conducted? What system can guar-
ntee  access to counseling and psychological care if needed?
ho  will be best positioned to provide the counseling needed?
ealth  care professionals, NGO staff, peer educators? There is
o question that availability of OTC tests could mean a more
imited  counseling experience and less direct contact with the
ealth  system.
There  has been recent debate globally as to the value of
utting  diminishing resources into the pre-test counseling
nd  consent processes that were  established in the eighties.
hile  data from those who  test positive have indicated that
 pre- and post-test counseling experience is critical both for
upport  and to create that ﬁrst critical link with the health
ystem,29 there is little evidence that typical pre-test counsel-
ng  impacts behaviors for those who  are negative.30 In fact,
ne  clinical trial found that there was  no decrease in STI/HIV
ncidence among STD clinic patients receiving rapid HIV tests
ith  patient-centered pre-test counseling compared to those
eceiving  a rapid test with information only.31 Required coun-
eling  may  even represent an obstacle to testing – both due
o  experienced stigma in the health establishment and due
o  the inaccessibility (distance, wait times) of clinics. In light
f  this fact, some have advocated for eliminating mandated
re-test counseling, which is often of variable quality,32 to put
ore  resources into effective post-test counseling and facil-
tating  linkage to care for HIV positives.33,34 An alternative
iew is that not every test requires the same level of counsel-
ng.  Instead, MSM  could be encouraged to test frequently (two
o  four times a year), but encouraged to undergo counseling
nly  once a year or on demand. The home testing debate may
e  instrumental in advancing discussions about the current,
raditional counseling model.4;1 8(3):239–244  241
There is also a broad debate about how linkage to
care  would be managed in the self-testing environment.
If users of OTC tests understand the need for conﬁrm-
atory testing, and recent evidence would suggest that
many  do, then the conﬁrmatory test can serve as the ﬁrst
‘link’  into the care system.35 Research on mechanisms to
facilitate  linkage in the context of self-testing will be criti-
cal.
What  are  the  potential  social  harms?
The potential social harms and unintended consequences
of  using home test kits and approaches to mitigate these
potential negative effects require attention. Concerns with
self-testing  include adverse emotional reactions to positive
tests,  risk compensation following a negative test, coercion
to  use tests, and potential partner violence when tests are
utilized  in relationships. In the recent study of OTC  testing
conducted in MSM in New York City, use of approximately
100 kits with casual partners prior to initiating sex resulted
in  10 positive results and no sexual intercourse nor vio-
lent  reactions following a positive result.24 There were  no
cases  of physical violence when the use of a test kit was
proposed and declined. Harm to self, though often the cen-
terpiece  of the argument against self-testing, has not been
documented in the age of ARTs.36 Because counseling oppor-
tunities  will necessarily be reduced with self-testing, support
mechanisms (including hot lines or 0–800 numbers, informa-
tional  brochures, web-support [video or chat], and electronic
or  mobile test result assistance) will need to be developed to
accompany  test kits.
Whether  an HIV negative self-test might encourage unsafe
sex  (discourage condom use) is an important question to
pose,  again driving home the importance of education around
the  window period. To date, the worries around risk com-
pensation have not been substantiated for other prevention
technologies in either PrEP trials37,38 or circumcision trials.39
There are other risks posed by taking test kits home: family
members or friends could ﬁnd the clearly marked HIV test-
ing  kits, threatening privacy. This may  necessitate creative
packaging and disposal materials. Further, pressure to test
from  friends or partners is a real concern. For sex workers any
forced  utilization by clients, pimps, or brothel owners could
have  severe consequences (as could use by sex workers on
their  clients). Finally, there is the potential that distribution of
home  test kits would encourage further withdrawal or alien-
ation  from the public health system, particularly for MSM  and
transgender  people already uncomfortable in the public sec-
tor.
In  order to mitigate potential social harms, partnership
with NGOs and other representative institutions related to
MSM  populations should be sought in ﬂeshing out plans for
research  and implementation. Community based organiza-
tions  have long been recognized as an important resource for
the  implementation and reinforcement of HIV/AIDS preven-
40tion  and control policies and programs. In Brazil, as well as
in  other developing countries, NGOs have also built an effec-
tive  network for social and psychological support for those
most  affected by HIV.41
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A  proposed  research  agenda
Overall, the net prevention potential for OTC testing for MSM
and  other populations is still poorly understood. Above all, it
remains largely uncertain whether the availability of OTC test
kits will bring about the anticipated increase in HIV testing
rates.  At least one randomized study of the impact of OraQuick
test  kit distribution on testing frequency among MSM will be
launched  in the US in 2014. It is also unclear whether the bene-
ﬁts  of increases in testing rates would be offset by fewer people
testing  in clinics, less linkage to care, and the reduced accuracy
of  OTC tests.42 It is also unknown whether people will seek
conﬁrmatory testing and link to care following use of a self-
test.  These larger questions will need to be studied regionally
–  as will aspects of demand and supply of OTC tests, includ-
ing  appropriate distribution channels for test kits that ensure
accessible  costs or distribution in the public sector, so as not
to  exclude the populations most in need of testing alterna-
tives.
Speciﬁc  to Brazil, where there is but one feasibility study
(that  we  are aware of) underway, we propose the following
research questions to support safe and accurate use of OTC
testing  in populations with the greatest need:
- What are the optimal mechanisms to ensure effective link-
age  to post-test counseling, conﬁrmatory testing, care, and
treatment?  What referral resources can be included in test
kits  and can feasibly be used to ensure follow-up for positive
tests?
-  What are the optimal support mechanisms to ensure safe
and  accurate use of test kits, minimizing social harms,
including in-kit resources, web  resources, hotlines, peer-
networks, and NGOs?
-  What is the optimal distribution system in Brazil to ensure
access  to test kits for those who most require testing and
are  less apt to access public services?
- How does availability of self-test kits affect testing decisions
(including when, where, and with whom to test), testing
frequency, and sexual behavior?
- What are the HIV testing needs of different sectors of the
diverse  ‘MSM’  population and how can they be met  using
OTC  tests?
There are currently plans to evaluate the implementation
of innovative HIV testing modalities, including self-testing,
targeting MSM  in Curitiba, in Southern Brazil, in collaboration
with  the CDC and the PEPFAR Key Population Implementation
Science Fund.
Implications  for  policy  and  practice
Pending research results, we believe that OTC testing might be
made available in a hybrid strategy in Brazil. First, self-testing
kits  could be introduced as an alternative testing option for
those  identiﬁed at health services as high risk (i.e. MSM, trans-
gender  populations, those seeking Post-Exposure Prophylaxis
(PEP),  sex workers, and partners in sero-discordant couples).
These  individuals could be offered home testing kits within 1 4;1  8(3):239–244
the SUS as an alternative to coming into the clinic for repeat
tests  or to take home to cover the window period (testing 2–3
months  later following a negative test at a health service). This
strategy  can both decrease the burden on existing testing ser-
vices  and empower individuals to utilize testing that meets
their  individual needs.
The  second strategy would be to offer kits for sale in phar-
macies,  which may  improve access for those who  prefer not to
attend clinics. Men tend to utilize services less frequently than
women  in Brazil, so this pharmacy-based strategy may  appeal
to  MSM. The concern with pharmacy sales is, of course, cost.
HIV  vulnerability is the highest in resource poor populations
who  may  not be able to purchase tests, which highlights the
importance  of making OTC tests available through the public
system  and/or via NGOs and other alternative testing settings,
such  as mobile units. The subsidized pharmacy system may
prove  a feasible option for those coming with prescriptions
from SUS.
Moving  ahead
Mounting the suggested research program will necessitate
political discussions, including the potential revision of cur-
rent  pre-test counseling practices. Indeed, self-conducted HIV
testing will challenge long-held beliefs about the delivery of
HIV/AIDS  prevention and care and requires a dialog between
the  public sector, health care providers and civil society. The
Brazilian  Ministry of Health is currently taking large steps
to  advance the country’s prevention and treatment agenda.
In  December 2013, the adoption of the test and treat strat-
egy  was  incorporated into the new national HIV treatment
guidelines. All individuals diagnosed with HIV infection will be
offered ARV treatment regardless of CD4 count. It is expected
that  this will lead to at least 100,000 new individuals living
with  HIV gaining access to combined antiretroviral therapy.
In  addition, Brazil is taking advantage of the local capacity
to  manufacture HIV rapid test kits, including oral ﬂuid kits,
which  should make HIV testing available to high-risk popu-
lations  outside of health services in settings such us mobile
units  and NGOs.
As  the HIV prevention and care leader in Latin America,
Brazil is in the position to explore research and partnerships
that  will prepare the country and the region for OTC HIV test-
ing.  The time has come to explore the potential of OTC  testing
as  an additional tool in the battle against HIV.
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